Monte Rosa Therapeutics

Historical price data

Monte Rosa Therapeutics is on a mission to redefine the druggable genome by developing precision molecular glue degraders (MGDs) that eliminate, rather than inhibit, pathogenic proteins. The company has rapidly advanced from its 2018 founding to a public entity with multiple clinical-stage assets, underscored by a landmark $2.1B+ partnership with Novartis for its lead immunology candidate, MRT-6160. Its strategy centers on leveraging the proprietary QuEEN™ discovery engine—integrating AI, structural biology, and proteomics—to systematically target novel protein surfaces and build a broad pipeline across high-value therapeutic areas.

QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) is an AI/ML-powered integrated discovery engine combining a proprietary MGD library, high-throughput screening, proteomics, structural biology, and geometric deep learning to rationally design molecular glue degraders that engage novel protein surfaces.

Monte Rosa competes with PROTAC pioneers (e.g., Arvinas, Nurix) and other molecular glue specialists (e.g., Kymera). Its differentiation lies in the QuEEN™ platform's AI-driven focus on discovering novel protein binding modes, potentially accessing a broader and more unique target space. Partnerships with Novartis and Roche provide validation and resources.